Sustained safety and efficacy of magnesium reabsorbable scaffold. 2-year follow-up analysis from first Magmaris multicenter Italian registry
Cardiovasc Revasc Med
Magnesium Reabsorbable Scaffold (MRS), is the newest reabsorbable technology with low thrombogenicity, short scaffolding time and almost complete resorption at 12-months (95%). Preliminary 12-months data in selected patients has shown that safety and efficacy are comparable with second generation Drug Eluting Stent (DES). Magmaris Multicenter registry showed 1-and 2-years clinical outcome on the first patients suitable for MRS enrolled in 4 Italian centers.
Reference: Sustained safety and efficacy of magnesium reabsorbable scaffold. 2-year follow-up analysis from first Magmaris multicenter Italian registry. Galli S, Troiano S, Palloshi A, Rapetto C, Pisano F, Aprigliano G, Leoncini M, Ravagnani P, Del Maestro M, Montorsi P. Cardiovasc Revasc Med. 2022 Jan 25:S1553-8389(22)00020-3.